Overview

  • Product nameAnti-KCNQ3 antibody
    See all KCNQ3 primary antibodies
  • Description
    Rabbit polyclonal to KCNQ3
  • SpecificityThis antibody is specific for KCNQ3 and does not detect KCNQ1, KCNQ2, KCNQ4 or KCNQ5.
  • Tested applicationsSuitable for: ICC/IF, ICC, IHC-Frmore details
  • Species reactivity
    Reacts with: Mouse, Rat, Human
  • Immunogen

    Recombinant fragment (proprietary-tag) corresponding to Rat KCNQ3 aa 1-71 (N terminal).

Properties

  • FormLiquid
  • Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
  • Storage bufferPreservative: 0.02% Sodium Azide
    Constituents: PBS, 1mg/ml BSA
  • Concentration information loading...
  • PurityImmunogen affinity purified
  • ClonalityPolyclonal
  • IsotypeIgG
  • Research areas

Applications

Our Abpromise guarantee covers the use of ab16228 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
ICC/IF
ICC
IHC-Fr
  • Application notesICC: Use at a concentration of 0.5 µg/ml.
    IF: Use at a concentration of 0.5 µg/ml.
    IHC-Fr: Use at a concentration of 0.5 µg/ml. This antibody gives a strong signal mainly in interneurons and astrocytes in the dentate region of rat hippocampal samples.

    Not tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.
  • Target

    • FunctionProbably important in the regulation of neuronal excitability. Associates with KCNQ2 or KCNQ5 to form a potassium channel with essentially identical properties to the channel underlying the native M-current, a slowly activating and deactivating potassium conductance which plays a critical role in determining the subthreshold electrical excitability of neurons as well as the responsiveness to synaptic inputs.
    • Tissue specificityPredominantly expressed in brain.
    • Involvement in diseaseDefects in KCNQ3 are the cause of benign neonatal epilepsy type 2 (EBN2) [MIM:121201]. Benign neonatal epilepsy is characterized by clusters of seizures occurring in the first days of life. Most patients have spontaneous remission by 12 months of age and show normal psychomotor development. The disorder is distinguished from benign familial infantile seizures by an earlier age at onset.
    • Sequence similaritiesBelongs to the potassium channel family. KQT (TC 1.A.1.15) subfamily. Kv7.3/KCNQ3 sub-subfamily.
    • DomainThe segment S4 is probably the voltage-sensor and is characterized by a series of positively charged amino acids at every third position.
    • Cellular localizationMembrane.
    • Information by UniProt
    • Database links
    • Alternative names
      • BFNC 2 antibody
      • BFNC antibody
      • BFNC2 antibody
      • EBN 2 antibody
      • EBN2 antibody
      • KCNQ 3 antibody
      • KCNQ3 antibody
      • KCNQ3_HUMAN antibody
      • KQT like 3 antibody
      • KQT-like 3 antibody
      • KV7.3 antibody
      • Potassium channel subunit alpha KvLQT3 antibody
      • Potassium channel voltage gated subfamily Q member 3 antibody
      • Potassium voltage gated channel KQT like protein 3 antibody
      • Potassium voltage gated channel KQT like subfamily member 3 antibody
      • Potassium voltage gated channel subfamily KQT member 3 antibody
      • Potassium voltage-gated channel subfamily KQT member 3 antibody
      • Voltage gated potassium channel subunit Kv7.3 antibody
      • Voltage-gated potassium channel subunit Kv7.3 antibody
      see all

    References for Anti-KCNQ3 antibody (ab16228)

    ab16228 has not yet been referenced specifically in any publications.

    Product Wall

    There are currently no Abreviews or Questions for ab16228.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"